{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:07:54Z","timestamp":1767164874559,"version":"build-2238731810"},"reference-count":88,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":963,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1111\/ijcp.12023","type":"journal-article","created":{"date-parts":[[2013,1,11]],"date-time":"2013-01-11T05:14:04Z","timestamp":1357881244000},"page":"139-156","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Implications of new anticoagulants in primary practice"],"prefix":"10.1155","volume":"67","author":[{"given":"A.","family":"Perez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. H.","family":"Eraso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. J.","family":"Merli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,11]]},"reference":[{"key":"10.1111\/ijcp.12023-BIB1|cit1","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition)","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest"},{"key":"10.1111\/ijcp.12023-BIB2|cit2","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition)","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"key":"10.1111\/ijcp.12023-BIB3|cit3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2459\/JCM.0b013e32832e490b","article-title":"The current role of anticoagulants in cardiovascular medicine","volume":"10","author":"DeCaterina","year":"2009","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1111\/ijcp.12023-BIB4|cit4","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"10.1111\/ijcp.12023-BIB5|cit5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5045\/kjh.2010.45.1.8","article-title":"Recent advances in the management of venous thromboembolism","volume":"45","author":"Ageno","year":"2010","journal-title":"Korean J Hematol"},{"key":"10.1111\/ijcp.12023-BIB6|cit6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev-med-062209-095159","article-title":"Novel oral Factor Xa and thrombin inhibitors in the management of thromboembolism","volume":"62","author":"Eriksson","year":"2011","journal-title":"Annu Rev Med"},{"key":"10.1111\/ijcp.12023-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and Factor Xa inhibitors in development","volume":"48","author":"Eriksson","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/ijcp.12023-BIB8|cit8","unstructured":"FDA once again delays approval of apixaban (Eliquis) 2012 http:\/\/cardiobrief.org\/2012\/06\/25\/fda-once-again-delays-approval-of-apixaban-eliquis\/"},{"key":"10.1111\/ijcp.12023-BIB9|cit9","unstructured":"Bayer Pharma AG Bayer\u2019s Xarelto \u00ae (rivaroxaban) granted priority review by US FDA to prevent secondary cardiovascular events in patients with ACS 2012 http:\/\/press.bayerhealthcare.com\/en\/press\/auth\/news-details-page.php\/14505\/2012-0089"},{"key":"10.1111\/ijcp.12023-BIB10|cit10","unstructured":"FDA rejects ACS indication for rivaroxaban (Xarelto) 2012 http:\/\/cardiobrief.org\/2012\/06\/21\/fda-rejects-acs-indication-for-rivaroxaban-xarelto\/"},{"key":"10.1111\/ijcp.12023-BIB11|cit11","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB12|cit12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12023-BIB13|cit13","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12023-BIB15|cit15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1160\/TH10-09-0601","article-title":"Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies","volume":"105","author":"Turpie","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1111\/ijcp.12023-BIB16|cit16","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB17|cit17","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12023-BIB18|cit18","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB19|cit19","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/ijcp.12023-BIB20|cit20","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12023-BIB21|cit21","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1160\/TH10-10-0679","article-title":"Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial","volume":"105","author":"Eriksson","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1111\/ijcp.12023-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"The RE-MOBILIZE Writing Committee","year":"2009","journal-title":"J Arthroplasty"},{"key":"10.1111\/ijcp.12023-BIB23|cit23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.thromres.2010.03.021","article-title":"Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials","volume":"126","author":"Friedman","year":"2010","journal-title":"Thromb Res"},{"key":"10.1111\/ijcp.12023-BIB24|cit24","doi-asserted-by":"crossref","first-page":"I9","DOI":"10.1161\/01.CIR.0000078469.07362.E6","article-title":"Risk factors for venous thromboembolism","volume":"107","author":"Anderson","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/ijcp.12023-BIB25|cit25","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB26|cit26","unstructured":"Cohen AT Spiro TE B\u00fcller HR et\u00a0al. Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients"},{"key":"10.1111\/ijcp.12023-BIB27|cit27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11239-011-0549-x","article-title":"Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol","volume":"31","author":"Cohen","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/ijcp.12023-BIB28|cit28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1055\/s-0037-1613887","article-title":"Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d\u2019Etude de la Thrombose de Bretagne Occidentale","volume":"83","author":"Oger","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1111\/ijcp.12023-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-125-1-199607010-00001","article-title":"The long-term clinical course of acute deep venous thrombosis","volume":"125","author":"Prandoni","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1111\/ijcp.12023-BIB30|cit30","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"The EINSTEIN Investigators","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"The EINSTEIN-PE Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","article-title":"Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep-vein thrombosis. The Botticelli DVT dose-ranging study","volume":"6","author":"Buller","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/ijcp.12023-BIB33|cit33","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB34|cit34","article-title":"A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II)","volume":"118","author":"Schulman","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"Suppl. 2","key":"10.1111\/ijcp.12023-BIB35|cit35","article-title":"Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism","volume":"9","author":"Schulman","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 2","key":"10.1111\/ijcp.12023-BIB36|cit36","article-title":"Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism","volume":"9","author":"Schulman","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/ijcp.12023-BIB37|cit37","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1111\/ijcp.12023-BIB38|cit38","doi-asserted-by":"crossref","first-page":"546S","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition)","volume":"133","author":"Singer","year":"2008","journal-title":"Chest"},{"key":"10.1111\/ijcp.12023-BIB39|cit39","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12023-BIB40|cit40","doi-asserted-by":"crossref","first-page":"531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation. Antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines (9th Edition)","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1111\/ijcp.12023-BIB41|cit41","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2009.11.025","article-title":"Rivaroxaban - once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study","volume":"159","author":"The Executive Steering Committee on behalf of the ROCKET AF Study Investigators","year":"2010","journal-title":"Am Heart J"},{"key":"10.1111\/ijcp.12023-BIB42|cit42","unstructured":"Hacke W Patel MR Becker RC et\u00a0al. 2010"},{"key":"10.1111\/ijcp.12023-BIB43|cit43","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB44|cit44","first-page":"232","article-title":"Quality of anticoagulation control among patients with atrial fibrillation","volume":"17","author":"Melamed","year":"2011","journal-title":"Am J Manag Care"},{"key":"10.1111\/ijcp.12023-BIB45|cit45","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1093\/eurheartj\/ehr134","article-title":"Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA","volume":"32","author":"Wieloch","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12023-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB47|cit47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"key":"10.1111\/ijcp.12023-BIB48|cit48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11239-006-9022-7","article-title":"Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM)","volume":"23","author":"Ansell","year":"2007","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/ijcp.12023-BIB49|cit49","unstructured":"Janssen Pharmaceuticals Inc Xarelto (rivaroxaban) Prescribing Information 2011 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202439s001lbl.pdf"},{"key":"10.1111\/ijcp.12023-BIB50|cit50","unstructured":"Bayer Pharma AG Xarelto \u00ae (rivaroxaban) Summary of Product Characteristics 2012 http:\/\/www.xarelto.com\/html\/downloads\/Xarelto-Prescribing_Information-May-2012.pdf"},{"key":"10.1111\/ijcp.12023-BIB51|cit51","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ahj.2009.08.026","article-title":"Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment","volume":"159","author":"Eikelboom","year":"2010","journal-title":"Am Heart J"},{"key":"10.1111\/ijcp.12023-BIB52|cit52","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB53|cit53","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB54|cit54","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ahj.2009.02.005","article-title":"Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran","volume":"157","author":"Ezekowitz","year":"2009","journal-title":"Am Heart J"},{"issue":"Suppl. 2","key":"10.1111\/ijcp.12023-BIB55|cit55","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0049-3848(10)00227-6","article-title":"Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score","volume":"125","author":"Connolly","year":"2010","journal-title":"Thromb Res"},{"key":"10.1111\/ijcp.12023-BIB56|cit56","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Newly identified events in the RE-LY trial","volume":"363","author":"Connolly","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB57|cit57","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJMp1103050","article-title":"Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran","volume":"364","author":"Beasley","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB58|cit58","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1586\/erc.11.21","article-title":"Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial","volume":"9","author":"Paikin","year":"2011","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1111\/ijcp.12023-BIB59|cit59","unstructured":"Boehringer Ingelheim International GmbH Pradaxa (dabigatran etexilate) Summary of Product Characteristics 2011 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf"},{"key":"10.1111\/ijcp.12023-BIB60|cit60","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/eurheartj\/ehp230","article-title":"New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?","volume":"30","author":"Van de Werf","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12023-BIB61|cit61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12023-BIB62|cit62","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2011.01.026","article-title":"Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome","volume":"161","author":"Gibson","year":"2011","journal-title":"Am Heart J"},{"key":"10.1111\/ijcp.12023-BIB63|cit63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB64|cit64","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"The APPRAISE Steering Committee and Investigators","year":"2009","journal-title":"Circulation"},{"key":"10.1111\/ijcp.12023-BIB65|cit65","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"10.1111\/ijcp.12023-BIB66|cit66","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12023-BIB67|cit67","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nrcardio.2012.18","article-title":"Oral factor Xa inhibitors for the long-term management of ACS","volume":"21","author":"Wisler","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"10.1111\/ijcp.12023-BIB68|cit68","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1111\/ijcp.12023-BIB69|cit69","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1160\/TH09-06-0361","article-title":"The clinical implications of new oral anticoagulants: will the potential advantages be achieved?","volume":"103","author":"Phillips","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1111\/ijcp.12023-BIB70|cit70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2009-09-241851","article-title":"The new oral anticoagulants","volume":"115","author":"Garcia","year":"2010","journal-title":"Blood"},{"key":"10.1111\/ijcp.12023-BIB71|cit71","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1179\/acb.2009.093","article-title":"Prevention and treatment of thromboembolic events in medical patients and new anticoagulants","volume":"64","author":"Balaratnam","year":"2009","journal-title":"Acta Clin Belg"},{"key":"10.1111\/ijcp.12023-BIB72|cit72","unstructured":"US Food and Drug Administration Pradaxa (dabigatran etexilate mesylate): drug safety communication - safety review of post-market reports of serious bleeding events 2011 http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm282820.htm"},{"key":"10.1111\/ijcp.12023-BIB73|cit73","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials","volume":"172","author":"Uchino","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1111\/ijcp.12023-BIB74|cit74","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7326\/0003-4819-157-1-201207030-00467","article-title":"Dabigatran: uncharted waters and potential harms","volume":"157","author":"Radecki","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1111\/ijcp.12023-BIB75|cit75","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/ijcp.12023-BIB76|cit76","article-title":"Apixaban, a direct Factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation","volume":"48","author":"Frost","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/ijcp.12023-BIB77|cit77","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/ijcp.12023-BIB78|cit78","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2125.2007.02898.x","article-title":"Development of oral anticoagulants","volume":"64","author":"Ma","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/ijcp.12023-BIB79|cit79","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/cpt1976195part1552","article-title":"Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect","volume":"19","author":"Yacobi","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/ijcp.12023-BIB80|cit80","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/ijcp.12023-BIB81|cit81","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/ijcp.12023-BIB82|cit82","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/ijcp.12023-BIB83|cit83","unstructured":"Bristol-Myers Squibb Coumadin tablets (warfarin sodium) Prescribing information 2010 http:\/\/packageinserts.bms.com\/pi\/pi_coumadin.pdf"},{"key":"10.1111\/ijcp.12023-BIB84|cit84","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/ijcp.12023-BIB85|cit85","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/ijcp.12023-BIB86|cit86","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/ijcp.12023-BIB87|cit87","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nrcardio.2010.101","article-title":"New antithrombotic agents - insights from clinical trials","volume":"7","author":"Paikin","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"10.1111\/ijcp.12023-BIB88|cit88","first-page":"476","article-title":"Warfarin--indications, risks and drug interactions","volume":"39","author":"Tadros","year":"2010","journal-title":"Aust Fam Physician"}],"updated-by":[{"DOI":"10.1111\/ijcp.12236","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T00:00:00Z","timestamp":1374451200000}}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12023","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T01:03:47Z","timestamp":1643331827000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12023"}},"subtitle":["New anticoagulants in primary practice"],"short-title":[],"issued":{"date-parts":[[2013,1,11]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12023","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1,11]]},"assertion":[{"value":"2013-01-11","name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}